Results 41 to 50 of about 5,892 (166)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

BMC Nephrology, 2019
Background The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to ...
Hayley Bennett, Phil McEwan, Karina Hamilton, Karl O’Reilly   +3 more
doaj   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease. [PDF]

Intern Med J
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Abdy ME, St Pierre K, Major E, Alexander SI, Cashmore B, Coolican H, Cullen V, Dawson J, Lambert K, Lee VW, Mallawaarachi A, Rangan G, Savige J, Varughese S, Tunnicliffe DJ, Mallett AJ, CARI Guidelines Steering Committee.   +16 more
europepmc   +2 more sources

Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5

Kidney International Reports
Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Akinari Sekine, Junichi Hoshino, Toshio Mochizuki, Shinya Nakatani, Saori Nishio, Tatsuya Suwabe, Hiroki Hayashi, Hirayasu Kai, Koichi Seta, Fumihiko Hattanda, Sumi Hidaka, Kazushige Hanaoka, Mahiro Kurashige, Hiroshi Kataoka, Kiyotaka Uchiyama, Keiji Shimazu, Eiji Ishikawa, Yosuke Shimada, Haruna Kawano, Ken Tsuchiya, Shigeo Horie, Ichiei Narita, Yoshitaka Isaka, Satoru Muto   +23 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

The spaghetti plotting of the annual liver growth rate before and after tolvaptan use.

, 2022
In the tolvaptan group, the median growth rate of TLV before tolvaptan use was 1.23 (range -6.9, 16.3) %/year and that after tolvaptan use was 2.4 (-8.6, 17.6) %/year. Although, the growth rate of TLV did not statistically change after tolvaptan use (p =
Akinari Sekine (4357189), Eiko Hasegawa (848440), Naoki Sawa (848442), Hiroki Mizuno (560647), Tatsuya Suwabe (848436), Masayuki Yamanouchi (848441), Junichi Hoshino (848432), Daisuke Ikuma (12102061), Yoshifumi Ubara (848444)   +8 more
core   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

Angewandte Chemie, Volume 138, Issue 25, 15 June 2026.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +2 more sources

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Tolvaptan

, 2014
Hyponatremia is a common and often under-recogonised clinical problem in oncologic practice. The recogonition of the cause of hyponatremia and initiation of appropriate and timely intervention can prevent morbidity and improve treatment tolerance.
Vineetha Binoy, Vanita Noronha, Bharath Rangarajan, Sachin Sharatchandra Hingmire   +3 more
core   +1 more source

Plant‐derived nanovesicles as potential drug delivery systems for topical use: Emerging applications in dermatology and cosmetology

VIEW, EarlyView.
Plant‐derived nanovesicles (PDNVs) are naturally secreted by fruit, vegetables, seeds, leaves and other natural sources. Used as drug delivery systems, they can combine intrinsic therapeutic activity, enhanced skin permeation and cargo‐carrying capacity, suitable for dermatological and cosmetic applications including hydration, antioxidant/anti ...
Dorotea Fiore, Beatrice Pellegrini, Antonia Mancuso, Maria Chiara Cristiano, Salvatore Panza, Donatella Paolino   +5 more
wiley   +1 more source

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes [PDF]

, 2016
Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Brouwer, Kenneth R., Freeman, Kimberly M., Slizgi, Jason R., Lu, Yang, Pan, Maxwell, Brock, William J., St Claire, Robert L., Brouwer, Kim L. R.   +7 more
core   +1 more source